All In Biotech

Drug Trial Radar · NCT00604890

Dose-Ranging Clinical Trial of Topical Creams Containing API 31510 for the Treatment of Superficial Basal Cell Carcinoma

Last checked: Nov 19, 2026Latest source record: Feb 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 186 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

186

Actual

Start

Mar 2008

Primary completion

Jan 2010

Study completion Jan 2010

Sponsor

Lead sponsor
BPGbioIndustry
Sponsor type
Industry
First posted
Jan 30, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the safety and tolerability of pharmaceutical compound (API 31510) topical cream topically applied to superficial basal cell carcinomas to obtain preliminary efficacy data for the treatment of superficial basal cell carcinomas by API 31510 topical cream. The study population will include one hundred and sixty (160) otherwise healthy male or female adults with one or more histologically confirmed superficial basal cell carcinoma lesions. One target lesion with an area of less than one inch will be designated for study treatment.

Conditions

  • Superficial Basal Cell Carcinoma

Interventions

  • API 31510 3% Topical CreamDrug

    Topical treatment 3% active cream applied to the lesion

  • API 31510 1.5% Topical CreamDrug

    Topical treatment 1.5% active cream applied to the lesion

  • PlaceboOther

    Topical treatment placebo applied to the lesion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Complete ResponseTime frame: 10 weeks

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • Burke Pharmaceuticals

    Hot Springs, Arkansas

  • Skin Surgery Medical Group, Inc.

    San Diego, California

  • Colorado Medical Research Center

    Denver, Colorado

  • Dermatology Associates and Research

    Coral Gables, Florida

  • Gwinnett Clinical Research

    Snellville, Georgia

  • Scott D. Glazer, M.D., S.C.

    Buffalo Grove, Illinois

  • Christie Clinic

    Champaign, Illinois

  • Long Island Skin Cancer and Dermatologic Surgery, PC

    Smithtown, New York

  • Oregon Dermatology and Research Center

    Portland, Oregon

  • Dermatology Clinical Research Center of San Antonio

    San Antonio, Texas

  • Education & Research Foundation

    Lynchburg, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.